Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Poor Influenza Efficacy Necessitates Shift From Egg-Based Manufacturing

By GlobalData | March 9, 2018

In February 2018, the US Centers for Disease Control and Prevention (CDC) reported 97 influenza-related pediatric deaths for the 2017–2018 influenza season, an alarmingly high number compared with recent years. These unsettling statistics reinforce the need to shift away from the traditional chicken egg-based approach of mass production of commercial influenza vaccines, which commonly induces a suboptimal immune response, according to GlobalData, a data and analytics company.

Instead, GlobalData believes vaccine manufacturers should embrace the modernization of commercial mass production of seasonal influenza vaccines developed from cell and recombinant vaccine construction technologies. These technologies are capable of producing vaccines that are better designed for combatting circulating strains of the influenza virus.

Inherent limitations associated with the egg-based vaccine manufacturing process undermine the potential antibody-antigen binding affinity needed to achieve consistently high vaccine efficacy from season to season. Specifically, hereditary constraints presented by the egg substrate increase the antigen differentiation between the vaccine being constructed via egg and the region of the virus surface protein antigen targeted by the vaccine.  The end result is a decrease in binding affinity of the induced antibodies created from a mismatched vaccine.

In contrast, cell-based and recombinant vaccines are not similarly constrained in design because their vaccine propagation is not egg-based. Sequiris, a leading influenza vaccine maker, has received FDA approval for its quadrivalent influenza vaccine, Flucelvax, which is an all cell-based candidate vaccine virus (CVV) derived from mammalian cells. Cell-based and recombinant vaccine production not only allow for direct incorporation of sequenced circulating influenza viruses, but can also be completed more quickly than the egg-based approach. The real-time strain surveillance relationship of this technology can provide the most effective seasonal influenza vaccine.

Gilbert Saint Jean, PhD, Healthcare Analyst at GlobalData, comments: “In order to best facilitate this shift away from egg-based technology, governments must modernize their partnerships with vaccine manufacturers. Current surveillance by the World Health Organization (WHO) and other institutions revolves around the six to eight month egg-substrate vaccine timeline. Overall vaccine efficacy improves with the newer technologies if their quicker manufacturing times are combined with government-provided seed virus submissions from increased surveillance at the global level for mutations in the antigenic target of flu vaccines.” 

Given the public outcry from this year’s seasonal influenza outbreak, along with the national security implications of a future severely virulent influenza pandemic, GlobalData believes that the transition to non-egg vaccine mass production technologies should be expedited as long as newer technologies demonstrate reliability, safety, and increased average vaccine efficacy. Further improvement in vaccine efficacy can be gained if trials of universal influenza vaccines, such as Vaccitech’s Invictus Phase II conserved antigen region study, prove successful.

(Source: GlobalData) 


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE